Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The genetic determinants of low-density lipoprotein cholesterol (LDL-C) levels in blood have been predominantly explored in European populations and remain poorly understood in Middle Eastern populations. We investigated the genetic architecture of LDL-C variation in Qatar by conducting a genome-wide association study (GWAS) on serum LDL-C levels using whole genome sequencing data of 13,701 individuals (discovery; n = 5,939, replication; n = 7,762) from the population-based Qatar Biobank (QBB) cohort. We replicated 168 previously reported loci from the largest LDL-C GWAS by the Global Lipids Genetics Consortium (GLGC), with high correlation in allele frequencies (R = 0.77) and moderate correlation in effect sizes (Beta; R = 0.53). We also performed a multi-ancestry meta-analysis with the GLGC study using MR-MEGA (Meta-Regression of Multi-Ethnic Genetic Association) and identified one novel LDL-C-associated locus; rs10939663 (SLC2A9; genomic control-corrected P = 1.25 × 10). Lastly, we developed Qatari-specific polygenic score (PGS) panels and tested their performance against PGS derived from other ancestries. The multi-ancestry-derived PGS (PGS000888) performed best at predicting LDL-C levels, whilst the Qatari-derived PGS showed comparable performance. Overall, we report a novel gene associated with LDL-C levels, which may be explored further to decipher its potential role in the etiopathogenesis of cardiovascular diseases. Our findings also highlight the importance of population-based genetics in developing PGS for clinical utilization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927683 | PMC |
| http://dx.doi.org/10.1016/j.jlr.2025.100752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Network Medicine-Based Repurposing of Mesalazine for Atherosclerosis Treatment.
J Cardiovasc Transl Res
September 2025
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519000, China.
Atherosclerosis remains a leading cause of cardiovascular disease and mortality worldwide, despite advancements in statin therapies. Here, we aimed to identify potential anti-atherosclerosis drugs by an integrated approach combining network medicine-based prediction with empirical validation. Among the top drugs predicted by the preferred algorithm, mesalazine─a drug traditionally used to treat inflammatory bowel disease, was selected for in vivo validation in ApoE mouse model of atherosclerosis.
View Article and Find Full Text PDFEvaluation of lipid profile and high sensitive C reactive protein levels among cigarette smokers in East Gojjam, Ethiopia.
Am Heart J Plus
October 2025
Department of Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Introduction: Cigarette smoking is a well-recognized independent risk factor for numerous cardiovascular disorders and contributes to the increasing morbidity and mortality associated with chronic heart diseases (CHD). This study aimed to evaluate how cigarette smoking affects lipid metabolism and inflammatory processes, along with other related mechanisms, in order to better understand the potential cardiovascular risks faced by smokers.
Objectives: To evaluate and compare the serum lipid profile and high-sensitivity C-reactive protein levels between cigarette smokers and non-smokers.
Prevalence and penetrance of pathogenic and likely pathogenic and gene variants linked to familial hypercholesterolemia and increased risk of ischemic heart disease.
Front Genet
August 2025
Federal Medical and Biologicl Agency, Moscow, Russia.
Background: Familial hypercholesterolemia (FH) is a prevalent hereditary disorder, with its monogenic form linked to an elevated risk of early-onset ischemic heart disease. Evaluating the prevalence and penetrance of pathogenic and likely pathogenic variants associated with this disorder would provide valuable information supporting routine FH screening of the general population. Such informed screening would facilitate early identification of at-risk individuals, enabling timely intervention and management.
View Article and Find Full Text PDFStatin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV.
J Clin Invest
September 2025
Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.
Background: Statin therapy lowers the risk of major adverse cardiovascular events (MACE) among people with HIV (PWH). Residual risk pathways contributing to excess MACE beyond low-density lipoprotein cholesterol (LDL-C) are not well understood. Our objective was to evaluate the association of statin responsive and other inflammatory and metabolic pathways to MACE in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
View Article and Find Full Text PDFIntroduction: Endothelial dysfunction has been reported in rheumatoid arthritis (RA) patients without classical cardiovascular risk factors, but findings remain inconsistent.
Objectives: To assess whether endothelial function is impaired in RA with moderate inflammatory burden in the absence of established cardiovascular risk factors.
Patients And Methods: This cross-sectional study was conducted in 64 patients with RA without classical CV risk factors and 60 healthy age- and sex-matched controls.